This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Global Blood Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Ted Love

Chief Executive Officer (CEO)

US$8.2m

Compensación total

Porcentaje del salario del CEO	8.7%
Permanencia del CEO	8.3yrs
Participación del CEO	1.4%
Permanencia media de la dirección	6.5yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ted Love en comparación con los beneficios de Global Blood Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2022	n/a	n/a	-US$322m
Mar 31 2022	n/a	n/a	-US$310m
Dec 31 2021	US$8m	US$716k	-US$303m
Sep 30 2021	n/a	n/a	-US$277m
Jun 30 2021	n/a	n/a	-US$266m
Mar 31 2021	n/a	n/a	-US$249m
Dec 31 2020	US$18m	US$661k	-US$248m
Sep 30 2020	n/a	n/a	-US$282m
Jun 30 2020	n/a	n/a	-US$286m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$10m	US$597k	-US$267m
Sep 30 2019	n/a	n/a	-US$220m
Jun 30 2019	n/a	n/a	-US$199m
Mar 31 2019	n/a	n/a	-US$182m
Dec 31 2018	US$10m	US$569k	-US$174m
Sep 30 2018	n/a	n/a	-US$166m
Jun 30 2018	n/a	n/a	-US$152m
Mar 31 2018	n/a	n/a	-US$135m
Dec 31 2017	US$8m	US$520k	-US$117m
Sep 30 2017	n/a	n/a	-US$103m
Jun 30 2017	n/a	n/a	-US$95m
Mar 31 2017	n/a	n/a	-US$89m
Dec 31 2016	US$1m	US$479k	-US$82m
Sep 30 2016	n/a	n/a	-US$71m
Jun 30 2016	n/a	n/a	-US$65m
Mar 31 2016	n/a	n/a	-US$58m
Dec 31 2015	US$2m	US$438k	-US$51m

Compensación vs. Mercado: Ted's total compensation ($USD8.19M) is above average for companies of similar size in the UK market ($USD2.71M).

Compensación vs. Ingresos: Ted's compensation has been consistent with company performance over the past year.

CEO

Ted Love (63 yo)

8.3yrs

Permanencia

US$8,193,309

Compensación

Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ted Love	President	8.3yrs	US$8.19m	1.37% $ 63.2m
Jeffrey Farrow	CFO & Principal Accounting Officer	6.5yrs	US$2.76m	0.040% $ 1.8m
Jung Choi	Chief Business & Strategy Officer	7.5yrs	US$2.73m	0.37% $ 17.2m
David Johnson	Chief Commercial Officer	4.6yrs	US$2.75m	0.084% $ 3.9m
Kim Smith-Whitley	Executive VP and Head of Research & Development	1.4yrs	US$2.98m	0.0089% $ 409.5k
David Phillips	Founder & Advisor	11.8yrs	sin datos	sin datos
Matthew Jacobson	Founder & Advisor	11.8yrs	sin datos	sin datos
Andrej Sali	Founder & Advisor	11.8yrs	sin datos	sin datos
Nazila Habibizad	Executive Vice President of Operations	2.5yrs	sin datos	0.062% $ 2.9m
Stephanie Yao	Senior Director of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Patricia Suvari	Chief Legal Officer & Secretary	6yrs	US$5.93m	0.064% $ 3.0m
Steven Immergut	Senior VP & Head of Corporate Communications	3.8yrs	sin datos	sin datos

6.5yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: 0IVZ's management team is seasoned and experienced (6.5 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ted Love	President	9.1yrs	US$8.19m	1.37% $ 63.2m
Mark Perry	Lead Independent Director	7.5yrs	US$348.28k	0.056% $ 2.6m
Wendy Yarno	Independent Director	4.8yrs	US$320.78k	0.017% $ 783.3k
Deval Patrick	Independent Director	2.4yrs	US$313.28k	0.013% $ 618.8k
Glenn Pierce	Independent Director	6.7yrs	US$318.28k	0.039% $ 1.8m
Philip Pizzo	Independent Director	7.1yrs	US$310.78k	0.013% $ 623.9k
Scott W. Morrison	Independent Director	6.8yrs	US$333.28k	0.0098% $ 454.8k
Dawn Svoronos	Independent Director	3.8yrs	US$316.36k	0.0080% $ 368.3k
Willie Brown	Advisor & Director Emeritus	less than a year	US$308.28k	0.058% $ 2.7m
Alexis Thompson	Independent Director	1.6yrs	US$735.61k	0.0049% $ 226.5k

5.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: 0IVZ's board of directors are considered experienced (5.8 years average tenure).

This company listing is no longer active

Global Blood Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

Executive Vice President of Operations recently sold US$314k worth of stock

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director

Recent updates

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Second quarter 2022 earnings released: US$1.26 loss per share (vs US$1.12 loss in 2Q 2021)

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

First quarter 2022 earnings released: US$1.26 loss per share (vs US$1.21 loss in 1Q 2021)

No longer forecast to breakeven

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Forecast to breakeven in 2024

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index

Global Blood Therapeutics, Inc. Announces Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK

Global Blood Therapeutics, Inc. Announces New Data from the Phase 2a HOPE-KIDS 1 Study

Global Blood Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: US$1.21 loss per share (vs US$1.20 loss in 1Q 2020)

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director

Revenue beats expectations

Global Blood Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Global Blood Therapeutics, Inc. Expands Access Protocol for Oxbryta in Pediatric Patients with Sickle Cell Disease

European Medicines Agency Accepts Global Blood Therapeutics, Inc.’s Marketing Authorization Application for Oxbryta (Voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition

Global Blood Therapeutics, Inc. Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

Global Blood Therapeutics, Inc. Initiates Early Access Program for Voxelotor

Revenue misses expectations

Global Blood Therapeutics, Inc. Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad